# Koligo Therapeutics Ltd — Form D

Koligo Therapeutics Ltd of SYDNEY, C3, a company, filed a Form D exempt-offering notice with the SEC on 2019-03-20. The offering totals $400K, of which $38K was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2019-03-20
- Form: D
- Accession: 0001771249-19-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $400K
- Amount sold: $38K
- Remaining: $362K
- Minimum investment: $2K
- Investors: 2
- Date of first sale: 2019-03-12
- Security types: equity
- Revenue range: $1,000,001 - $5,000,000
- SEC file number: 021-335252

## Issuer

- Name: Koligo Therapeutics Ltd
- CIK: 0001771249
- Entity type: Corporation
- Jurisdiction: AUSTRALIA
- Incorporated: 2018
- Address: LEVEL 5, SYDNEY, C3, 2000
- Phone: 01161292999690

## Officers, directors & promoters (8)

| Name | Role | Location |
| --- | --- | --- |
| Robert Clisdell | Director | Sydney NSW, C3 |
| Peter James | Director | Sydney, C3 |
| Matthew Lehman | Director | FARGO, ND |
| Jethro Marks | Director | Sydney NSW, C3 |
| Stuart Williams | Director | Sydney NSW, C3 |
| Matthew Lehman | Executive Officer | FARGO, ND |
| Ariel Sivikofsky | Executive Officer | NORTH SYDNEY NSW, C3 |
| Stuart Williams | Executive Officer | Sydney NSW, C3 |

## More

- [CIK 1771249 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1771249&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001771249-19-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.